AGP Executive Report
Last update: 2 hours agoChina-UK Pharma Dealmaking: Sino Biopharm signed new pacts with AstraZeneca and GSK to deepen respiratory drug rights in China, including AstraZeneca’s up to $1.9B deal tied to a lung-disease candidate. Dengue Treatment Push: Serum Institute of India and DNDi will test an SII monoclonal antibody for dengue in an international Phase III trial (Brazil, Malaysia, Thailand) starting Q1 2027, with a parallel Phase III in India. Indonesia Vaccine Progress: BPOM backed an mRNA dengue vaccine prototype from University of Indonesia and Tsinghua, calling it a step toward broader health sovereignty. Care Access & Wellness: CeraVe supported World Skin Health Day with volunteer dermatologists for free consultations and education. Public Health Under Pressure: India’s NFHS-6 omission of key indicators raises concerns for tracking anaemia and sanitation progress. Clinical Milestone in Africa: Chinese medical teams performed South Sudan’s first laparoscopic bilateral inguinal hernia tension-free repair at Juba Teaching Hospital. Health Rumors Abroad: U.S. Sen. Mitch McConnell’s prolonged hospitalization continues to fuel calls for clearer health updates.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
